417 related articles for article (PubMed ID: 15608067)
21. Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA.
Liang KW; Nishikawa M; Liu F; Sun B; Ye Q; Huang L
Gene Ther; 2004 Jun; 11(11):901-8. PubMed ID: 14985786
[TBL] [Abstract][Full Text] [Related]
22. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
23. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy.
Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S
Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298
[TBL] [Abstract][Full Text] [Related]
24. Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres.
Baranov A; Glazkov P; Kiselev A; Ostapenko O; Mikhailov V; Ivaschenko T; Sabetsky V; Baranov V
Gene Ther; 1999 Aug; 6(8):1406-14. PubMed ID: 10467365
[TBL] [Abstract][Full Text] [Related]
25. Comparison between gentamycin and exon skipping treatments to restore ryanodine receptor subtype 2 functions in mdx mouse duodenum myocytes.
Dabertrand F; Mironneau J; Henaff M; Macrez N; Morel JL
Eur J Pharmacol; 2010 Feb; 628(1-3):36-41. PubMed ID: 19944091
[TBL] [Abstract][Full Text] [Related]
26. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy.
Mann CJ; Honeyman K; McClorey G; Fletcher S; Wilton SD
J Gene Med; 2002; 4(6):644-54. PubMed ID: 12439856
[TBL] [Abstract][Full Text] [Related]
27. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
[TBL] [Abstract][Full Text] [Related]
28. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
29. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
30. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
31. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
[TBL] [Abstract][Full Text] [Related]
32. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
[TBL] [Abstract][Full Text] [Related]
33. DMD transcript imbalance determines dystrophin levels.
Spitali P; van den Bergen JC; Verhaart IE; Wokke B; Janson AA; van den Eijnde R; den Dunnen JT; Laros JF; Verschuuren JJ; 't Hoen PA; Aartsma-Rus A
FASEB J; 2013 Dec; 27(12):4909-16. PubMed ID: 23975932
[TBL] [Abstract][Full Text] [Related]
34. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
35. [Dystrophin expression and pathology of diaphragm muscles of mdx mice after xenogenic bone marrow stem cell transplantation].
Zhang YN; Zhang C; Yu MJ; Wang SH; Li MS; Huang H; Xiong F; Feng SW; Liu TY; Lu XL
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):53-8. PubMed ID: 16495176
[TBL] [Abstract][Full Text] [Related]
36. The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice.
Anderson CL; De Repentigny Y; Cifelli C; Marshall P; Renaud JM; Worton RG; Kothary R
Mol Ther; 2006 Nov; 14(5):724-34. PubMed ID: 16807118
[TBL] [Abstract][Full Text] [Related]
37. Electroporation of corrective nucleic acids (CNA) in vivo to promote gene correction in dystrophic muscle.
Kapsa RM; Wong SH; Quigley AF
Methods Mol Biol; 2008; 423():405-19. PubMed ID: 18370218
[TBL] [Abstract][Full Text] [Related]
38. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
39. Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice.
Sirsi SR; Schray RC; Guan X; Lykens NM; Williams JH; Erney ML; Lutz GJ
Hum Gene Ther; 2008 Aug; 19(8):795-806. PubMed ID: 18647087
[TBL] [Abstract][Full Text] [Related]
40. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity.
Malerba A; Boldrin L; Dickson G
Nucleic Acid Ther; 2011 Aug; 21(4):293-8. PubMed ID: 21851223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
